학술논문
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial
Document Type
article
Author
Amy S. Clark; Christina Yau; Denise M. Wolf; Emanuel F. Petricoin; Laura J. van ‘t Veer; Douglas Yee; Stacy L. Moulder; Anne M. Wallace; A. Jo Chien; Claudine Isaacs; Judy C. Boughey; Kathy S. Albain; Kathleen Kemmer; Barbara B. Haley; Hyo S. Han; Andres Forero-Torres; Anthony Elias; Julie E. Lang; Erin D. Ellis; Rachel Yung; Debu Tripathy; Rita Nanda; Julia D. Wulfkuhle; Lamorna Brown-Swigart; Rosa I. Gallagher; Teresa Helsten; Erin Roesch; Cheryl A. Ewing; Michael Alvarado; Erin P. Crane; Meredith Buxton; Julia L. Clennell; Melissa Paoloni; Smita M. Asare; Amy Wilson; Gillian L. Hirst; Ruby Singhrao; Katherine Steeg; Adam Asare; Jeffrey B. Matthews; Scott Berry; Ashish Sanil; Michelle Melisko; Jane Perlmutter; Hope S. Rugo; Richard B. Schwab; W. Fraser Symmans; Nola M. Hylton; Donald A. Berry; Laura J. Esserman; Angela M. DeMichele
Source
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
Subject
Language
English
ISSN
2041-1723
Abstract
HER2-targeted therapy improves patient’s outcome in early breast cancer. Here, the authors present the efficacy and biomarker analysis of two HER2-targeted combinations (ado-trastuzumab emtansine plus pertuzumab and paclitaxel, trastuzumab and pertuzumab) in the context of the neoadjuvant I-SPY2 phase 2 adaptive platform trial for early breast cancer at high risk of recurrence.